Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 15/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 5/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213826 | 0.89 | CHEK1 (0.64) | CHEK1AURKBAURKAJAK2CHEK2 | |
| SCHEMBL4816804 | 0.87 | CHEK1 (0.58) | CHEK1AURKBAURKAJAK2CHEK2 | |
| SCHEMBL4815973 | 0.83 | CHEK1 (1.00) | CHEK1AURKBAURKAJAK2CHEK2 | |
| SCHEMBL4817404 | 0.83 | CHEK1 (1.00) | CHEK1AURKBAURKAJAK2CHEK2 | |
| SCHEMBL6218491 | 0.82 | CHEK1 (0.55) | CHEK1AURKBAURKAJAK2CHEK2 | |
| SCHEMBL6218486 | 0.82 | CHEK1 (0.55) | CHEK1AURKBAURKAJAK2CHEK2 | |
| SCHEMBL4806341 | 0.82 | CHEK1 (0.57) | CHEK1AURKBAURKAJAK2CHEK2 | |
| SCHEMBL6783292 | 0.79 | CHEK1 (0.58) | CHEK1AURKBAURKACHEK2CSF1R | |
| SCHEMBL6217279 | 0.78 | CHEK1 (0.68) | CHEK1AURKBRPS6KB1MARK3FLT3 | |
| SCHEMBL6213992 | 0.77 | CHEK1 (0.56) | CHEK1AURKBAURKAJAK2CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CHEK1 73/4885AURKB 204/4885AURKA 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.